Title Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease. Journal, issue, pages J. Med. Chem. , Vol. 65, Page 7818-7832, Year 2022Publish date Dec 9, 2021 (structure data deposition date) AuthorsDampalla, C.S. / Rathnayake, A.D. / Galasiti Kankanamalage, A.C. / Kim, Y. / Perera, K.D. / Nguyen, H.N. / Miller, M.J. / Madden, T.K. / Picard, H.R. / Thurman, H.A. ...Dampalla, C.S. / Rathnayake, A.D. / Galasiti Kankanamalage, A.C. / Kim, Y. / Perera, K.D. / Nguyen, H.N. / Miller, M.J. / Madden, T.K. / Picard, H.R. / Thurman, H.A. / Kashipathy, M.M. / Liu, L. / Battaile, K.P. / Lovell, S. / Chang, K.O. / Groutas, W.C. External links J. Med. Chem. / PubMed:35638577Methods X-ray diffraction Resolution 1.45 - 2.1 Å Structure data PDB-7t3y : Structure viewer Structure of MERS 3CL protease in complex with inhibitor 8c Method : X-RAY DIFFRACTION / Resolution : 1.9 Å
PDB-7t3z : Structure viewer Structure of MERS 3CL protease in complex with inhibitor 9c Method : X-RAY DIFFRACTION / Resolution : 1.95 Å
PDB-7t40 : Structure viewer Structure of MERS 3CL protease in complex with inhibitor 10c Method : X-RAY DIFFRACTION / Resolution : 1.7 Å
PDB-7t41 : Structure viewer Structure of MERS 3CL protease in complex with inhibitor 14c Method : X-RAY DIFFRACTION / Resolution : 2.1 Å
PDB-7t42 : Structure viewer Structure of SARS-CoV-2 3CL protease in complex with inhibitor 2c Method : X-RAY DIFFRACTION / Resolution : 1.6 Å
PDB-7t43 : Structure viewer Structure of SARS-CoV-2 3CL protease in complex with inhibitor 3c Method : X-RAY DIFFRACTION / Resolution : 1.7 Å
PDB-7t44 : Structure viewer Structure of SARS-CoV-2 3CL protease in complex with inhibitor 4c Method : X-RAY DIFFRACTION / Resolution : 1.45 Å
PDB-7t45 : Structure viewer Structure of SARS-CoV-2 3CL protease in complex with inhibitor 7c Method : X-RAY DIFFRACTION / Resolution : 1.65 Å
PDB-7t46 : Structure viewer Structure of SARS-CoV-2 3CL protease in complex with inhibitor 8c Method : X-RAY DIFFRACTION / Resolution : 1.45 Å
PDB-7t48 : Structure viewer Structure of SARS-CoV-2 3CL protease in complex with inhibitor 9c Method : X-RAY DIFFRACTION / Resolution : 1.9 Å
PDB-7t49 : Structure viewer Structure of SARS-CoV-2 3CL protease in complex with inhibitor 10c Method : X-RAY DIFFRACTION / Resolution : 1.75 Å
PDB-7t4a : Structure viewer Structure of SARS-CoV-2 3CL protease in complex with inhibitor 11c Method : X-RAY DIFFRACTION / Resolution : 1.8 Å
PDB-7t4b : Structure viewer Structure of SARS-CoV-2 3CL protease in complex with inhibitor 14c Method : X-RAY DIFFRACTION / Resolution : 1.6 Å
Chemicals ChemComp-F5L : Structure viewer (1R,2S)-1-hydroxy-2-{[N-({[7-(2-methylpropanoyl)-7-azaspiro[3.5]nonan-2-yl]oxy}carbonyl)-L-leucyl]amino}-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-F8C : Structure viewer (1S,2S)-1-hydroxy-2-{[N-({[7-(2-methylpropanoyl)-7-azaspiro[3.5]nonan-2-yl]oxy}carbonyl)-L-leucyl]amino}-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-FHS : Structure viewer (1S,2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]-2-{[N-({[7-(phenylacetyl)-7-azaspiro[3.5]nonan-2-yl]oxy}carbonyl)-L-leucyl]amino}propane-1-sulfonic acid
ChemComp-FEY : Structure viewer (1R,2S)-2-{[N-({[(2r,4R)-7-acetyl-7-azaspiro[3.5]non-5-en-2-yl]oxy}carbonyl)-L-leucyl]amino}-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-FV5 : Structure viewer (1R,2S)-1-hydroxy-2-{[N-({[7-(methanesulfonyl)-7-azaspiro[3.5]nonan-2-yl]oxy}carbonyl)-L-leucyl]amino}-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-FVE : Structure viewer (1S,2S)-1-hydroxy-2-{[N-({[7-(methanesulfonyl)-7-azaspiro[3.5]nonan-2-yl]oxy}carbonyl)-L-leucyl]amino}-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-PG4 : Structure viewer TETRAETHYLENE GLYCOL / precipitant*YM
ChemComp-FWI : Structure viewer (1R,2S)-2-{[N-({[1-(tert-butoxycarbonyl)azetidin-3-yl]methoxy}carbonyl)-L-leucyl]amino}-1-hydroxy-3-[(3R)-2-oxo-2,3-dihydro-1H-pyrrol-3-yl]propane-1-sulfonic acid
ChemComp-FZI : Structure viewer (1S,2S)-2-{[N-({[1-(tert-butoxycarbonyl)azetidin-3-yl]methoxy}carbonyl)-L-leucyl]amino}-1-hydroxy-3-[(3R)-2-oxo-2,3-dihydro-1H-pyrrol-3-yl]propane-1-sulfonic acid
ChemComp-FIK : Structure viewer (1S,2S)-2-[(N-{[(2-acetyl-2-azaspiro[3.3]heptan-6-yl)oxy]carbonyl}-L-leucyl)amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-FIW : Structure viewer (1R,2S)-1-hydroxy-2-{[N-({[2-(2-methylpropanoyl)-2-azaspiro[3.3]heptan-6-yl]oxy}carbonyl)-L-leucyl]amino}-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-FN2 : Structure viewer (1S,2S)-1-hydroxy-2-[(N-{[(2-methyl-2-azaspiro[3.3]heptan-6-yl)oxy]carbonyl}-L-leucyl)amino]-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-FP8 : Structure viewer (1R,2S)-1-hydroxy-2-[(N-{[(2-methyl-2-azaspiro[3.3]heptan-6-yl)oxy]carbonyl}-L-leucyl)amino]-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-ESS : Structure viewer (1R,2S)-2-[(N-{[(2-azaspiro[3.3]heptan-6-yl)oxy]carbonyl}-L-leucyl)amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-ET6 : Structure viewer (1S,2S)-1-hydroxy-2-{[N-({[2-(methanesulfonyl)-2-azaspiro[3.3]heptan-6-yl]oxy}carbonyl)-L-leucyl]amino}-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-EW9 : Structure viewer (1S,2S)-2-{[N-({[7-(tert-butoxycarbonyl)-7-azaspiro[3.5]nonan-2-yl]oxy}carbonyl)-L-leucyl]amino}-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-EQS : Structure viewer (1S,2S)-2-[(N-{[(7-cyano-7-azaspiro[3.5]nonan-2-yl)oxy]carbonyl}-L-leucyl)amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-EO6 : Structure viewer (1R,2S)-2-[(N-{[(7-cyano-7-azaspiro[3.5]nonan-2-yl)oxy]carbonyl}-L-leucyl)amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
Source middle east respiratory syndrome-related coronavirus (isolate united kingdom/h123990006/2012) severe acute respiratory syndrome coronavirus 2 Keywords HYDROLASE/HYDROLASE INHIBITOR / PROTEASE / MERS 3CL protease Inhhibitors / hydrolase / HYDROLASE-HYDROLASE INHIBITOR complex / COVID-19 / severe acute respiratory syndrome coronavirus 2 / SARS-CoV-2 3CL protease Inhhibitors